Abstract
Importance Treatment options for Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on the efficacy and safety profiles.
Objective To assess if the effect estimate of any intervention improves the outcomes and safety profile.
Data sources PubMed, Embase, Cochrane Central were searched from December 1, 2019 to May 11, 2020.
Study selection Any prospective/retrospective clinical study on SARS-CoV-2 patients ≥18 years of age with report on therapeutic interventions.
Data synthesis and extraction Data was screened and extracted by two independent investigators.
Main outcomes and measures The primary outcome was all-cause in-hospital mortality. The secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, progression to severe disease, median time for clinical recovery and anti-viral clearance. Pooled rates and odds ratios (OR) were calculated.
Results A total of 29 studies with 5207 participants were included in the analysis. The pooled all-cause in-hospital mortality rate was 12.8% (95%CI: 8.1%-17.4%) in intervention arm. There was no significant difference in mortality between both arms overall (OR: 1.36, 95% CI: 0.97-1.89). The mortality was significantly higher in the Hydroxychloroquine (HCQ) group compared to control: (1.86, 95% CI: 1.38 – 2.50). The need for mechanical ventilation in patients with mild-moderate disease was 13.5% vs 9.8% in intervention and control groups, with no significant difference (OR: 1.58, 95% CI: 0.60 – 4.15).The median duration for viral clearance in the intervention arm was 6.1 (IQR: 4.3 – 8.8) days and control arm was 9 (IQR: 4.5 – 14) days, with no significant difference between the groups (p = 0.37). There was no significant difference between pooled adverse event rates in intervention and control groups: 34% vs 29.5% (OR: 1.44, 95% CI: 0.70 – 2.94), respectively. However, incidence of adverse events was significantly higher in HCQ sub-group (OR: 3.88, 95% CI: 1.60 – 9.45, I2 = 0%). There was no significant difference in other secondary outcomes.
Conclusion and relevance The use of hydroxychloroquine was associated with increased mortality and adverse event rates. No other therapeutic intervention including Lopinavir/Ritonavir, Remdesivir or Tocilizumab seem to alter the natural course of the disease. There is a further need for well-designed randomized clinical trials.
Article summary line The use of hydroxychloroquine was associated with increased mortality and adverse event rates in Severe acute respiratory syndrome-related coronavirus-2 infection and other therapeutic interventions did not show any difference in outcomes
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No source of funding to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was needed for this study as this is a systematic review and no patient information was disclosed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data in the manuscript is original and was created by the authors involved in this manuscript
Abbreviations
- SARS-CoV-2 -
- Severe Acute Respiratory Syndrome related Coronavirus-2
- HCQ –
- Hydroxychloroquine
- COVID-19 –
- Coronavirus disease 2019
- PRISMA –
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RCT –
- Randomized Controlled Trials
- NNT –
- Number needed to treat
- NNH –
- Number needed to harm
- IQR –
- Interquartile range
- CI –
- Confidence interval
- OR –
- Odds ratio
- NIH –
- National Institute of Health
- FDA –
- Food and Drug Administration
- WHO –
- World Health Organization
